TCS 46bCAS# 302799-86-6 |
- Calyculin A
Catalog No.:BCC2457
CAS No.:101932-71-2
- Calcineurin Autoinhibitory Peptide
Catalog No.:BCC2456
CAS No.:148067-21-4
- DL-AP3
Catalog No.:BCC2459
CAS No.:20263-06-3
- Ceramide
Catalog No.:BCC2458
CAS No.:3102-57-6
- Fostriecin sodium salt
Catalog No.:BCC2460
CAS No.:87860-39-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 302799-86-6 | SDF | Download SDF |
PubChem ID | 9863010 | Appearance | Powder |
Formula | C22H23N3O | M.Wt | 345.44 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one | ||
SMILES | C1CN(CCC1CC2=CC=CC=C2)CC#CC3=CC4=C(C=C3)NC(=O)N4 | ||
Standard InChIKey | JJEXWPHPFZLTCU-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H23N3O/c26-22-23-20-9-8-18(16-21(20)24-22)7-4-12-25-13-10-19(11-14-25)15-17-5-2-1-3-6-17/h1-3,5-6,8-9,16,19H,10-15H2,(H2,23,24,26) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Orally active, subtype-selective GluN1A/GluN2B (formally NR1A/NR2B) NMDA receptor antagonist (IC50 values are 5.3, 35000 and > 100000 nM for GluN1A/2B (NR1A/2B), GluN1A/2B (NR1A/2B) and GluN1A/2C (NR1A/2C) receptor subtypes respectively). Potentiates the effect of L-DOPA in 6-OHDA-lesioned rats following oral administration. |
TCS 46b Dilution Calculator
TCS 46b Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.8949 mL | 14.4743 mL | 28.9486 mL | 57.8972 mL | 72.3715 mL |
5 mM | 0.579 mL | 2.8949 mL | 5.7897 mL | 11.5794 mL | 14.4743 mL |
10 mM | 0.2895 mL | 1.4474 mL | 2.8949 mL | 5.7897 mL | 7.2371 mL |
50 mM | 0.0579 mL | 0.2895 mL | 0.579 mL | 1.1579 mL | 1.4474 mL |
100 mM | 0.0289 mL | 0.1447 mL | 0.2895 mL | 0.579 mL | 0.7237 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3,4,5-Trimethoxycinnamyl alcohol
Catalog No.:BCN5212
CAS No.:30273-62-2
- Bisline
Catalog No.:BCN2062
CAS No.:30258-28-7
- Rosiglitazone HCl
Catalog No.:BCC2269
CAS No.:302543-62-0
- Potassium 7-hydroxynaphthalene-1-sulfonate
Catalog No.:BCN8289
CAS No.:30252-40-5
- 1-Hydroxybaccatin I
Catalog No.:BCN5211
CAS No.:30244-37-2
- Ingenol
Catalog No.:BCN2333
CAS No.:30220-46-3
- Effusanin A
Catalog No.:BCN5210
CAS No.:30220-43-0
- Arenobufagin 3-hemisuberate
Catalog No.:BCN7837
CAS No.:30219-16-0
- Retinoic acid
Catalog No.:BCN2185
CAS No.:302-79-4
- DL-Alanine
Catalog No.:BCN8539
CAS No.:302-72-7
- Aconitine
Catalog No.:BCN1014
CAS No.:302-27-2
- Hydroxyprogesterone acetate
Catalog No.:BCC8997
CAS No.:302-23-8
- Ciliobrevin A
Catalog No.:BCC3939
CAS No.:302803-72-1
- Ro 01-6128
Catalog No.:BCC7922
CAS No.:302841-86-7
- Ro 67-4853
Catalog No.:BCC7921
CAS No.:302841-89-0
- Dasatinib (BMS-354825)
Catalog No.:BCC1281
CAS No.:302962-49-8
- 2-Amino-N-(2-chloro-6-methylphenyl) thiazole-5-carboxamide
Catalog No.:BCC8551
CAS No.:302964-24-5
- Clinofibrate
Catalog No.:BCC5020
CAS No.:30299-08-2
- Heliotrine
Catalog No.:BCN1982
CAS No.:303-33-3
- Lasiocarpine
Catalog No.:BCN2001
CAS No.:303-34-4
- Methenolone enanthate
Catalog No.:BCC9029
CAS No.:303-42-4
- Gossypol
Catalog No.:BCN2702
CAS No.:303-45-7
- Ochratoxin A
Catalog No.:BCC7008
CAS No.:303-47-9
- Coenzyme Q10
Catalog No.:BCN5954
CAS No.:303-98-0
Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[(11)C]one, as a potent NR(1A)/2B subtype selective NMDA PET radiotracer.[Pubmed:14642584]
Bioorg Med Chem. 2003 Dec 1;11(24):5401-8.
Recently, a new series of potent and highly subtype-selective 1-(heteroarylalkynyl)-4-benzylpiperidine antagonists of the NMDA receptors has been described by Pfizer Laboratories. In this series, 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-one (1) was identified as a selective antagonist for the NR1(A)/2B subtype, displaying IC(50) values for inhibition of the NMDA responses of 5.3 nM for this subtype (compared to NR1(A)/2A: 35 microM and NR1(A)/2C>100 microM) and was active in rat at a relatively low dosage (10mg/kg po). Derivative 1 has been synthesized in four chemical steps in good overall yield and labelled with carbon-11 at its benzoimidazolone ring using [(11)C]phosgene. The pharmacological profile of [(11)C]-1 was evaluated in vivo in rats with biodistribution studies and brain radioactivity monitored with intracerebral radiosensitive beta-microprobes. The brain uptake of [(11)C]-1 was extremely low (0.07% I.D./mL on average at 30 min) and rather uniform across the different brain structures. This in vivo brain regional distribution of [(11)C]-1 did not match with autoradiographic or binding data obtained with other NR2B subtype-selective NMDA ligands. Competition studies with ifenprodil (20 mg/kg, ip, 30 min before the radiotracer injection) failed to demonstrate specific binding of the radiotracer in the brain. In view of these results, and especially considering the low brain penetration of the radiotracer, [(11)C]-1 does not have the required properties for imaging NMDA receptors using positron emission tomography.
Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines.[Pubmed:10978188]
J Med Chem. 2000 Sep 7;43(18):3408-19.
4-[4-(4-Benzylpiperidin-1-yl)but-1-ynyl]phenol (8) and 4-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]phenol (9) are potent NR1A/2B receptor antagonists (IC(50) values 0.17 and 0.10 microM, respectively). Administered intraperitoneally, they both potentiated the activity of L-DOPA in the unilaterally 6-hydroxydopamine-lesioned (6-OHDA) rat, a model of Parkinson's disease. However, compound 9 was not active orally, likely due to rapid first-pass metabolism of the phenol moiety. The phenol was replaced by several bicyclic heterocyclic systems containing an NH group to function as a H-bond donor in the hope that these would be less likely to undergo rapid metabolism. In general, indoles, indazoles, benzotriazoles, indolones, and isatins gave analogues with weaker NR1A/2B activity than the parent phenols, while benzimidazolones and benzimidazolinones gave equipotent or more potent analogues. The preference for a para arrangement between the H-bond donor and the linking acetylene moiety was confirmed, and a propyne link was preferred over a butyne link. Substitution on the benzyl group or a 4-hydroxyl group on the piperidine had little effect on NR1A/2B potency; however, 4-hydroxypiperidines demonstrated slightly improved selectivity for NR1A/2B receptors versus alpha-1 adrenergic and dopamine D2 receptor affinity. From this study, 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1, 3-dihydrobenzoimidazol-2-one (46b) was identified as a very potent, selective NR1A/2B receptor antagonist (IC(50) value 0.0053 microM). After oral administration at 10 and 30 mg/kg, 46b potentiated the effects of L-DOPA in the 6-OHDA-lesioned rat and seemed to have improved oral bioavailability but lower brain penetration compared to phenol 9.